Expression of B7-H3 correlates with PD-L1 and poor prognosis in patients with cervical cancer

12Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: The purpose of this study was to investigate B7 homolog 3 (B7-H3) expression patterns and define its associations with programmed cell-death ligand 1 (PD-L1), patholo-gical features, and survival in patients with cervical cancer. Patients and Methods: Immunohistochemical staining was used to investigate B7-H3 and PD-L1 expression in tissue microarrays from 552 patients with stage IB1 and IIA1 cervical cancer, including 406 with squamous cell carcinoma and 146 with endocervical adenocarcinoma. Results: B7-H3 was expressed in the tumor cells (TCs) of 32.1% of the samples as well as in the stromal cells of 92.9% of the specimens. B7-H3 was co-expressed with PD-L1 in 21.0% of the samples, while only one or the other was expressed in 41.7% of the samples. B7-H3 expression in TCs was more frequent in squamous cell carcinoma, PD-L1-positive samples, and tissues from patients with lymph node metastasis; moreover, its expression was an independent predictor of shorter survival. Conclusion: B7-H3 positivity in TCs is a promising prognostic biomarker, and targeting B7-H3 alone or in combination with PD-1/PD-L1 may be a potential immunotherapeutic strategy for patients with cervical cancer.

Cite

CITATION STYLE

APA

Zhang, Q., Zong, L., Zhang, H., Xie, W., Yang, F., Sun, W., … Zhang, Y. (2021). Expression of B7-H3 correlates with PD-L1 and poor prognosis in patients with cervical cancer. OncoTargets and Therapy, 14, 4275–4283. https://doi.org/10.2147/OTT.S318082

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free